Cover Image
市場調查報告書

Neratinib(HER2陽性乳癌治療藥): 開發平台分析及市場預測

Neratinib (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

出版商 GlobalData 商品編碼 237582
出版日期 內容資訊 英文 65 Pages
訂單完成後即時交付
價格
Back to Top
Neratinib(HER2陽性乳癌治療藥): 開發平台分析及市場預測 Neratinib (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023
出版日期: 2014年09月30日 內容資訊: 英文 65 Pages
簡介

HER2陽性乳癌是全球第2大女性癌症,在初期階段發現的話5年存活率幾乎為100%,但若在後期階段才發現的話存活率便會急速降低。HER2陽性細胞具攻擊性,比傳統HER2陰性類型的整體存活率都低。就在這樣的情形下1998年Herceptin (Trastuzumab)的HER2標靶治療為治療帶來了革命,讓整體存活率接近到陰性類型。同時更創造出以HER2為直接標的之治療方法這個莫大的市場。以Tykerb為首,透過組合各種化療來延長陽性患者的壽命。今後由於美國、歐盟五國、日本、中國高齡人口的增加,預計HER2陽性型市場也將成長。預測Neratinib一旦發售,到2018年HER2陽性乳癌市場上將達到1,200萬美元。此外該市場預計到2023年將達到9,000萬美元。

本報告提供HER2陽性乳癌治療藥的治療藥物Neratinib調查分析,提供您疾病概要和治療指南,競爭情形,產品資訊,銷售額預測等彙整資料。

第1章 目錄

第2章 簡介

  • 分析的背景
  • 相關報告
  • 近期預定出版的相關報告

第3章 疾病概要

  • 病因論及病理學
    • 病因論
    • 病理學
  • 基本的乳房生物組織
  • 乳癌 病期分類
  • 預後診斷
  • 生活品質(QOL)
  • 症狀

第4章 疾病管理

  • 治療概要
    • 乳癌 (階段0∼IB)
    • 局部進行性及局部 乳癌 (階段IB∼IIIA)
    • 轉移性 HER2-陽性 乳癌 (階段IV)

第5章 競爭評估

  • 概要

第6章 未滿足需求及機會

  • 概要
  • 腦轉移
    • 未滿足需求
    • Gap分析
    • 機會
  • 抗性:HER2標靶治療
    • 未滿足需求
    • Gap分析
    • 機會

第7章 開發平台評估

  • 概要
  • 臨床開發上的有潛力藥劑

第8章 Neratinib

  • 概要
  • 有效性
  • 安全性
  • 與給藥處方
  • 潛在的臨床及商業性位置
  • SWOT分析
  • 預測

第9章 附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC468DFR

GlobalData has released its new PharmaPoint Drug Evaluation report, "Neratinib (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023". HER2-positive breast cancer is the second most common cancer in the world and the most common cancer in women worldwide. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the HER2-positive breast cancer market, with coverage of multiple settings of the disease including neoadjuvant, adjuvant, first-, second-, third, and fourth-line metastatic.

Puma Biotechnology's neratinib is an orally-administered TKI that binds irreversibly, targeting HER1, HER2, and HER4. Neratinib inhibits HER2 at a different site than the currently marketed HER2-targeted therapies, which Puma believes will make it effective in patients who have developed resistance to these other treatments.

Scope

  • Overview of HER2-Positive Breast Cancer, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Neratinib including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Neratinib for the top eight countries from 2013 to 2023.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and China.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for HER2-Positive Breast Cancer
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Neratinib performance
  • Obtain sales forecast for Neratinib from 2013-2023 in top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and China)

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Basic Breast Anatomy
  • 3.3. Breast Cancer Staging
  • 3.4. Prognosis
  • 3.5. Quality of Life
  • 3.6. Symptoms

4. Disease Management

  • 4.1. Treatment Overview
    • 4.1.1. Treatment of Early-Stage Breast Cancer (Stage 0 to Stage IB)
    • 4.1.2. Treatment of Locally-Advanced and Regional Breast Cancer (Stage IB to IIIA)
    • 4.1.3. Treatment of Metastatic HER2-Positive Breast Cancer (Stage IV)

5. Competitive Assessment

  • 5.1. Overview

6. Unmet Need and Opportunity

  • 6.1. Overview
  • 6.2. Brain Metastases
    • 6.2.1. Unmet Need
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunity
  • 6.3. Resistance to HER2-Targeting Therapies
    • 6.3.1. Unmet Need
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunity

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Promising Drugs in Clinical Development

8. Neratinib

  • 8.1. Overview
  • 8.2. Efficacy
  • 8.3. Safety
  • 8.4. Dosing and Formulation
  • 8.5. Potential Clinical and Commercial Positioning
  • 8.6. SWOT Analysis
  • 8.7. Forecast

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Diagnosed HER2-Positive Breast Cancer Patients
    • 9.4.2. Percent Drug-Treated Patients
    • 9.4.3. General Pricing Assumptions
    • 9.4.4. Generic Erosion
    • 9.4.5. Pricing of Pipeline Agents
  • 9.5. Primary Research - KOLs Interviewed for this Report
  • 9.6. Primary Research - Prescriber Survey
  • 9.7. About the Authors
    • 9.7.1. Analyst
    • 9.7.2. Therapy Area Director
    • 9.7.3. Global Head of Healthcare
  • 9.8. About GlobalData
  • 9.9. Disclaimer

List of Tables

  • Table 1: AJCC Stage Definitions for Breast Cancer
  • Table 2: Prognosis for Breast Cancer in the US
  • Table 3: Treatment Guidelines for HER2-Positive Breast Cancer
  • Table 4: Unmet Need and Opportunity in HER2-Positive Breast Cancer
  • Table 5: Product Profile - Neratinib
  • Table 6: Neratinib SWOT Analysis, 2013
  • Table 7: Global Sales Forecast ($m) for Neratinib, 2013-2023
  • Table 8: HER2-Positive Breast Cancer Incidence, 2013-2023
  • Table 9: Average Body Weight and Surface Area Across the 8MM
  • Table 10: Average Annual Cost of Therapy ($) - Neratinib, Third Line
  • Table 11: Physicians Surveyed by Country

List of Figures

  • Figure 1: Basic Breast Anatomy, Including Key Lymph Nodes
  • Figure 2: HER2-Positive Breast Cancer - Phase II-III Pipeline, 2013
  • Figure 3: Neratinib's Clinical Development
  • Figure 4: Clinical and Commercial Positioning of neratinib.
Back to Top